Addex Therapeutics Ltd ADXN

SWX: ADXN | ISIN: CH0029850754   30/04/2025
0,060 CHF (+3,82%)
(+3,82%)   30/04/2025

30 april 2025 · Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery · Persbericht

25 april 2025 · Addex Reports Full Year 2024 Financial Results and Provides Corporate Update · Persbericht

24 april 2025 · Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025 · Persbericht

17 april 2025 · Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 · Persbericht

8 januari 2025 · Addex to Present at the 2025 Swiss Equities Baader Conference · Persbericht

22 november 2024 · Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

11 november 2024 · Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 · Persbericht

30 september 2024 · Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update · Persbericht

19 september 2024 · Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit · Persbericht

4 september 2024 · Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

27 augustus 2024 · Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration · Persbericht

22 juli 2024 · Addex’s Partner Discontinues ADX71149 development in Epilepsy · Persbericht

15 juli 2024 · Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) · Persbericht

12 juli 2024 · Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) · Persbericht

1 juli 2024 · Addex Shareholders Approve All Resolutions at Annual General Meeting · Persbericht

6 juni 2024 · Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update · Persbericht

5 juni 2024 · Addex Convenes Annual General Meeting 2024 · Persbericht

31 mei 2024 · Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 · Persbericht

8 mei 2024 · Addex to Present at Bio€quity Europe 2024 · Persbericht

29 april 2024 · Addex Provides Update on ADX71149 Phase 2 Epilepsy Study · Persbericht

Mijn selecties